The abstract is read at the publisher; the summary is JClub's.
Tumor-derived PCSK9 drives precursor-like macrophage M2 polarization in peritoneal metastasis, impairing T-cell function via NF-κB–IL-10 signaling and worsening immunosuppression.
- Why it matters: Peritoneal metastasis has an immunosuppressive tumor microenvironment, but the central regulators of immune suppression and actionable targets remain unclear.
- What they did: Integrated single-cell RNA-seq from 19 clinical samples with bulk RNA-seq datasets mapped the immune landscape, then mechanistic and preclinical tests evaluated PCSK9 inhibition alone and with anti-PD-1 after chemotherapy, including rabbit PIPAC delivery.
- The result: PCSK9 inhibition reversed macrophage polarization and reprogrammed the TME toward an antitumor state by boosting T-cell activation and recruitment through the Cxcl16–Cxcr6 axis, supporting schedule-dependent benefit and efficacy with PIPAC in rabbits.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.